Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma
Year: 2020
Type: article
Study design: Clinical Trial
Source: European Urology
Institutions: City Of Hope National Medical Center, City of Hope, Institut Gustave Roussy, Georgetown Lombardi Comprehensive Cancer Center, University of Pavia, Istituti Clinici Scientifici Maugeri, Fondazione IRCCS Istituto Nazionale dei Tumori, AVEO Oncology (United States), Beth Israel Deaconess Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3085486789